Quest Diagnostics Inc
DGX- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001022079
In the last 90 days, Quest Diagnostics Inc insiders filed 0 open-market purchases and 3 sales; 1,112 institutions reported holding it in 13F filings for Q2 2026, worth $22.2B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $8.32M in total
- 3
- 13F holdersQ2 2026, +52 vs. previous quarter
- 1,112
- 13F valueReported value at the end of Q2 2026
- $22.2B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DGX, Q2 2026
No superinvestor reported holding DGX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Quest Diagnostics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)5:05 PM ET | Sep 1 | 2 days | Davis J. E.CEO and President | SSale | −10.0K | $242.72 | −$2.43M | −7.6%122.4K after | 10b5-1 |
| Aug 31, 2026 (view filing)4:37 PM ET | Aug 28 | 3 days | Prevoznik Michael ESVP & General Counsel | SSale | −22.7K | $243.11 | −$5.51M | −37.6%37.6K after | 3 lots10b5-1 |
| Jul 29, 2026 (view filing)5:04 PM ET | Jul 28 | 1 day | Delaney Mark ESVP & Chief Commercial Officer | SSale | −1.60K | $235.18 | −$376.3K | −13.4%10.3K after | 10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4 | 4 days | Kuppusamy KarthikSVP, Clinical Solutions | SSale | −8.15K | $200.00 | −$1.63M | −37.6%13.5K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Davis J. E.CEO and President | SSale | −10.0K | $194.14 | −$1.94M | −7.0%132.4K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Doherty Catherine T.EVP, Regional Businesses | SSale | −5.56K | $206.21 | −$1.15M | −7.6%67.1K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Prevoznik Michael ESVP & General Counsel | SSale | −3.88K | $206.21 | −$799.7K | −9.4%37.6K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Plewman PatrickSVP for Diagnostic Services | SSale | −2.85K | $206.21 | −$588.7K | −15.8%15.2K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Kuppusamy KarthikSVP, Clinical Solutions | SSale | −2.63K | $204.86 | −$538.4K | −16.4%13.4K after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Doherty Catherine T.EVP, Regional Businesses | SSale | −632 | $207.73 | −$131.3K | −0.9%67.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Quest Diagnostics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,275,411 | $1.97B | 0.03% | +103,119+1.1% | Added |
| Vanguard Capital Management LLC | 7,233,394 | $1.53B | 0.03% | +87,722+1.2% | Added |
| Vanguard Portfolio Management LLC | 6,131,045 | $1.30B | 0.06% | +49,645+0.8% | Added |
| State Street Corp | 5,516,643 | $1.17B | 0.03% | +135,822+2.5% | Added |
| Price T Rowe Associates Inc | 5,444,986 | $1.15B | 0.12% | −853,001−13.5% | Reduced |
| Boston Partners | 4,744,473 | $1.00B | 0.89% | +732,241+18.3% | Added |
| JPMorgan Chase & Co | 3,520,438 | $748.6M | 0.04% | −326,018−8.5% | Reduced |
| Geode Capital Management, LLC | 3,137,873 | $662.6M | 0.04% | +51,565+1.7% | Added |
| Morgan Stanley | 2,460,497 | $521.5M | 0.03% | −19,223−0.8% | Reduced |
| EdgePoint Investment Group Inc. | 2,247,568 | $476.4M | 3.60% | +3,699+0.2% | Added |